611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
'Double-Edged Sword': Lung Cancer Radiation Rx May Raise Heart Attack RiskYour Drinking Water May Harbor Cancer-Causing Nitrate: StudyNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodChemoimmunotherapy Regimen Approved to Treat DLBCLCancer Survivors Predicted to Top 22 Million by 2030Guard Your Skin Against the Summer Sun'Focused' Radiation Could Lighten Treatment Burden for Early Breast Cancer1 in 4 Cancer Survivors Faces 'Financial Hardship' Due to Medical CostsFew Prostate Cancer Patients Are Getting Checkups They NeedTesticular Cancer Treatment Unlikely to Trigger Birth DefectsIs MRI Screening Worth It for Breast Cancer Survivors?Obamacare May Have Helped Close 'Race Gap' in Cancer CareObamacare May Have Boosted Fight Against Ovarian CancerCould 2 Prostate Cancer Drugs Fight Disease in Earlier Stages?Newer Drug Extends Lives of Young Breast Cancer PatientsU.S. Cancer Cases, Deaths Continue to FallA New Way to Fight a Previously 'Inoperable' Pancreatic CancerCancer Patients Vaping in Growing NumbersColon Cancer Striking More Under 50, and More Often in Western StatesAlex Trebek Says His Pancreatic Cancer Is 'Near Remission'Blood Test Could Spot Multiple Cancer Types, Researchers SayFirst PI3K Inhibitor Approved for Metastatic, Advanced Breast CancerAggressive Uterine Cancer on the Rise, Especially in Blacks: StudyColon Cancer Screenings Increase When Medicaid ArrivesPoor Diet Might Raise Your Cancer Risk'Watchful Waiting' Less Likely for Black Prostate Cancer PatientsAggressive Approach to Pancreatic Cysts May Prevent Dreaded CancerColon Cancer Increasingly Striking the Young WorldwideTrans Women Have Raised Odds of Breast Cancer, But Risk Still Small: StudyIs That Prostate Cancer Worth Treating? Chromosomes May TellLooking to Whales for Insight on Human CancersIs AI a New Weapon in Breast Cancer Detection?Use of Meds for Enlarged Prostate Might Delay a Cancer DiagnosisDoes Hormone Therapy for Prostate Cancer Raise Dementia Risk?Red Tape Means Many Cancer Patients Get Radiation Treatments LateDevice Spots Lymphedema Early in Breast Cancer Patients, to Help Stop ItGene Therapy May Help Fight Tough-to-Treat Blood CancerHealth Tip: Managing Nausea for Cancer PatientsOne High Dose of Radiation May Be Enough for Early Prostate CancerMany Cardiologists Ill-Equipped to Treat Heart Disease in Cancer SurvivorsStudy Supports Radiation for Early, Hormone-Driven Breast CancerNot All Cervical Cancer Rates Are DecliningMedical Marijuana Use Rising Among Cancer PatientsWith Weeks to Live, Many Cancer Patients Try Useless TreatmentsBalversa Approved for Advanced Bladder CancerChemo Drug Shortages Have Little Effect on Cancer Care: StudyMany Cancer Patients Take Alternative Meds But Don't Tell Their DoctorsNew 'Cancer Vaccine' Attacks Tumors From WithinAHA News: How Can Therapy for Heart Attack Patients Help Cancer Survivors?Researchers Seek Firefighters for Data on Cancer Risk
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemoimmunotherapy Regimen Approved to Treat DLBCL


HealthDay News
Updated: Jun 11th 2019

new article illustration

TUESDAY, June 11, 2019 (HealthDay News) -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug Administration announced today. The combination was approved for patients whose disease has progressed or returned after at least two previous therapies.

Approval was based on a study of 80 patients with relapsed or refractory DLBCL randomly assigned to receive either Polivy with bendamustine and rituximab or bendamustine and rituximab alone. Researchers found a complete response rate of 40 percent with Polivy plus bendamustine and rituximab compared with 18 percent with bendamustine and rituximab alone. Twenty-five patients achieved a partial or complete response with Polivy plus bendamustine and rituximab; 64 percent of these patients had a duration of response of six months or longer and 48 percent achieved a duration of response of at least one year.

The most commonly reported side effects of the combination of Polivy plus bendamustine and rituximab included neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, fever, decreased appetite, and pneumonia.

Patients should be closely monitored for infusion-related reactions, low blood counts, fatal or serious infections, tumor lysis syndrome, hepatotoxicity, and progressive multifocal leukoencephalopathy. The FDA noted that women of reproductive age should be advised to use effective contraception during treatment and for three months following the last dose, and those who are pregnant or breastfeeding should not be treated with Polivy.

Approval of Polivy was granted to Genentech.

More Information